Penicillin: The Discovery That Almost Remained in the Laboratory

The story of penicillin did not begin with a carefully designed plan to develop a new medicine. It began with an unexpected observation in a contaminated bacterial culture plate.

In 1928, Scottish bacteriologist Alexander Fleming noticed that mould had grown in one of his plates and that the bacteria surrounding it had stopped growing. What could easily have been dismissed as laboratory contamination appeared to be something worth investigating.

Fleming later demonstrated that the mould produced a substance that spread into the surrounding medium and inhibited the growth of certain bacteria. He named it penicillin.

The discovery was promising, but it was not yet a usable medicine.

A Discovery Ahead of Its Time

Penicillin was highly unstable and extremely difficult to isolate, purify, and produce in quantities suitable for medical use.

Fleming studied its properties and published his findings in 1929. However, the scientific tools and production methods available at the time were not sufficient to transform the substance into a practical treatment.

For years, penicillin remained scientifically important but therapeutically limited.

This reveals one of the central lessons of its story: science can discover something transformative before it possesses the means to make full use of it.

The Oxford Team Reopens the Case

In 1939, Ernst Boris Chain and Howard Florey returned to Fleming’s earlier findings as part of a broader research programme into antibacterial substances at the University of Oxford.

Chain viewed penicillin’s instability as a scientific challenge worth investigating, while Florey was interested in its activity against staphylococci. They quickly understood that developing it into a medicine would require a multidisciplinary team.

Among the researchers involved was Norman Heatley, who played a critical role in developing methods to measure penicillin’s activity, extract it from culture fluids, and produce it in a more stable and usable form.

The team began cultivating the mould, extracting and purifying its active substance, and studying its safety and effectiveness. The process was difficult. Producing even a small amount of penicillin required large volumes of culture fluid, and much of the substance could be lost during extraction and purification.

The Experiment That Changed the Project

In 1940, the Oxford team conducted a decisive experiment involving mice. The animals were infected with lethal bacteria. Some received penicillin, while others remained untreated.

The mice treated with penicillin survived. Those that did not receive it died.

The experiment demonstrated that penicillin could do more than inhibit bacteria in a laboratory dish. It could protect a living organism from a serious bacterial infection.

From that point forward, the question was no longer whether penicillin worked. The challenge was producing enough of it to treat human patients.

Florey’s laboratory gradually became a small production centre. The researchers used specially designed ceramic vessels and improvised equipment to cultivate the mould and extract the active substance. According to Oxford’s History of Science Museum, producing enough penicillin to treat a single case of sepsis initially required approximately 2,000 litres of culture fluid.

Medical Success Reveals a Larger Problem

Systematic treatment trials began in Oxford in 1941.

The first patient to receive a full course of penicillin showed a significant improvement after developing a severe bacterial infection. However, the available supply ran out before his treatment could be completed. The infection returned, and he later died.

The result was tragic, but it exposed a problem that was just as important as discovering the drug itself: an effective treatment cannot save lives if it cannot be produced in sufficient quantities.

Penicillin was no longer only a scientific challenge. It had become a challenge of manufacturing, engineering, funding, and large-scale production.

From a Small Laboratory to an Industrial Project

Britain’s industrial capacity was heavily occupied by the demands of the Second World War. Producing penicillin on the required scale was therefore extremely difficult.

In 1941, Florey and Heatley travelled to the United States to seek scientific and industrial support.

A broad collaboration began involving government laboratories, fermentation specialists, pharmaceutical manufacturers, and chemical engineers. These groups searched for more productive strains of mould, improved the culture medium, and developed deep-tank fermentation methods suitable for industrial production.

Scaling up was not simply a matter of placing more mould inside a larger container. The process required new systems for aeration, mixing, cooling, and foam control, together with more efficient methods for extracting and purifying penicillin without destroying it.

In March 1944, the first commercial plant for the large-scale production of penicillin through deep-tank fermentation opened in Brooklyn, New York.

Through cooperation among researchers, engineers, governments, and manufacturers, production increased dramatically. Penicillin moved from being a scarce experimental substance to a treatment available to growing numbers of patients.

It transformed the treatment of bacterial infections and helped usher in the modern antibiotic era.

Three Names and One Nobel Prize

In 1945, the Nobel Prize in Physiology or Medicine was awarded jointly to Alexander Fleming, Ernst Boris Chain, and Howard Walter Florey for the discovery of penicillin and its curative effect in infectious diseases.

Each represented an essential stage of the journey:

Fleming observed the phenomenon and discovered its antibacterial effect.

Chain helped revive the research and isolate the active substance.

Florey led the team that demonstrated its effectiveness in living organisms and advanced it toward clinical use.

However, the achievement extended far beyond three individuals. It also depended on the Oxford team, including Norman Heatley and other researchers and physicians, followed by government laboratories, engineers, and manufacturers who helped turn the discovery into a widely available medicine.

Why the Story of Penicillin Still Matters?

Scientific breakthroughs are often presented as sudden moments in which a brilliant individual discovers something that changes the world. Penicillin tells a more realistic story.

Fleming’s observation was essential, but it was not sufficient.

The discovery needed people who were willing to revisit it years later, understand its potential, develop methods to purify it, demonstrate its effectiveness, test it in patients, and find a way to manufacture it safely at scale.

Penicillin shows that innovation does not end with the original idea. Major breakthroughs also depend on the ability to translate knowledge into application, experiments into treatments, and laboratory success into solutions that can reach the people who need them.

The penicillin revolution was not created by discovery alone. It emerged from the complete process that followed: research, collaboration, development, manufacturing, and execution.

Some of history’s greatest transformations begin with a small observation. Their true impact appears only when someone carries them from the laboratory into the world.

References

• The Nobel Prize in Physiology or Medicine 1945

• Presentation Speech for the 1945 Nobel Prize in Physiology or Medicine

• The Discovery of Penicillin, Sir William Dunn School of Pathology, University of Oxford

• Original Penicillin Culture and Specimen, History of Science Museum, University of Oxford

• Discovery and Development of Penicillin, American Chemical Society

• Penicillin and Its Early Therapeutic Use, University of Oxford